SEC Form 4 · accession 0001179110-19-002928
Inotiv, Inc. · NOTVQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Leasure Jr.
Officer — President and CEO · Director
Period of report
Feb 28, 2019
Accepted (ET)
Mar 1, 2019 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000720154
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Feb 28, 2019 | P | 8,900 | $1.51 | A | 79,615 | D | |
| Common SharesF2 | Mar 1, 2019 | P | 10,000 | $1.62 | A | 89,615 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.55, inclusive. The reporting person undertakes to provide to Bioanalytical Systems, Inc., any security holder of Bioanalytical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.56 to $1.65, inclusive. The reporting person undertakes to provide to Bioanalytical Systems, Inc., any security holder of Bioanalytical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.